Aptivus Labeling Should Note Added Efficacy With Fuzeon, Committee Says
Executive Summary
Labeling for Boehringer Ingelheim's HIV therapy Aptivus should note that tipranavir is most efficacious when used in combination with certain HIV therapies, particularlyFuzeon, members of FDA's Antiviral Drugs Advisory Committee said May 19
You may also be interested in...
Aptivus Clears FDA For HIV; B.I. To Conduct Therapeutic Monitoring Study
Boehringer Ingelheim has agreed to develop a pilot study in therapeutic drug monitoring for its HIV therapy Aptivus (tipranavir)
Aptivus Clears FDA For HIV; B.I. To Conduct Therapeutic Monitoring Study
Boehringer Ingelheim has agreed to develop a pilot study in therapeutic drug monitoring for its HIV therapy Aptivus (tipranavir)
J&J Entry Into HIV Market Will Be Protease Inhibitor In 2006
Johnson & Johnson hopes to have its first approved treatment for HIV on the market by 2006